
News|Articles|October 19, 2012
FDA warns of serious blood disorder resulting from abuse of Opana ER
FDA has warned patients of thrombotic thrombocytopenic purpura (TTP), a serious blood disorder, resulting from misuse of oxymorphone hydrochloride extended-release tablet (Opana ER, Endo).
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicare Part D redesign reshapes market
2
A conversation with Tiffany Phung, Pharm.D., CSP, about how patient outcomes drive specialty pharmacy strategy
3
The sleep doctor who lives with a disorder he treats
4
Managing Chronic Disease Shouldn't Feel Like a Full-Time Job
5




















